Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) – 2021 to 2026

$3,850.00$5,850.00

Published on: March 26, 2021
Clear
SKU: GMS-1157 Category:

OVERVIEW

The market for hemato oncology testing is projected to hit USD 5.12 billion by 2026, rising at a CAGR of 12.3% over the forecast period, owing to the COVID-19 pandemic. The growing prevalence of hematological cancer, increased awareness of personalized medicines, and increased collaborations to develop new assays are driving growth in this market. The effect of COVID-19 on the market for the years 2020 and beyond is detailed in the study.

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 1

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 2

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 3

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 4

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 5

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 6

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 7

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid), Non-Hodgkin’s Lymphoma), End-User (Hospitals, Clinical Laboratories), Technology (NGS, PCR, IHC) - 2021 to 2026 8

TABLE OF CONTENT

1 Global Hemato Oncology Testing Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Hemato Oncology Testing Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Hemato Oncology Testing Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Hemato Oncology Testing Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Hemato Oncology Testing Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Hemato Oncology Testing Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Hemato Oncology Testing Market – By Product & Service (Market Size – &
million/billion)
8.1 Services
8.2 Assay Kits

9 Global Hemato Oncology Testing Market – By Cancer Type
9.1 Leukemia
9.2 Lymphoma
9.3 Other

10 Global Hemato Oncology Testing Market – By Technology
10.1 PCR
10.2 IHC
10.3 NGS
10.4 Cytogenetics
10.5 Others

11 Global Hemato Oncology Testing Market – By End-User
11.1 PCR
11.2 IHC
11.3 NGS
11.4 Cytogenetics
11.5 Others

12 Global Hemato Oncology Testing Market – By Geography (Market Size – & million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa

13 Global Hemato Oncology Testing Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships

14 Global Hemato Oncology Testing Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 F. Hoffman-La Roche Ltd.
14.3 Abbott Laboratories
14.4 Bio-Rad Laboratories, Inc.
14.5 Qiagen N.V.
14.6 Archerdx, Inc.
14.7 Arup Laboratories Inc.
14.8 Asuragen, Inc.
14.9 Illumina, Inc.
14.10 Thermo Fisher Scientific, Inc.
14.11 Molecularmd (Subsidiary of Icon PLC)
14.12 Company 11 & more

15 Global Hemato Oncology Testing Market – Appendix
15.1 Sources
15.2 Abbreviations